News
$109 million to fund Brain-Heart Interconnectome project to study brain-heart disorders
The CHEO Research Institute (CHEO RI) and the Lochmüller research group is excited to participate in a new initiative funded by the Canada First Research Excellence Fund (CFREF) to establish a first-of-its-kind multidisciplinary program dedicated to the research of brain-heart conditions to lead a paradigm shift in the study, prevention, diagnosis and treatment of these conditions that will benefit patients in Canada and around the world.
8.8 million euros for accelerated drug repurposing for rare neurological disorders
CHEO RI has received funding to participate in a multi-million Euro consortium established under the EU’s ‘Horizon Europe’ funding stream to accelerate therapeutic development for patients in Canada and around the world with neuromuscular diseases.
Lochmuller Lab clinical research webpage update
With a new searchable list of the ongoing clinical trials at our sites in Ottawa, it’s now easier than ever to stay up-to-date on the clinical research trials that our team is involved in.
New publication: Periostin as a blood biomarker of muscle cell fibrosis, cardiomyopathy and disease severity in myotonic dystrophy type 1
This collaborative international study identifies periostin as a novel biomarker candidate for Myotonic dystrophy type 1 (DM1) and suggests that it may serve as a novel stratification biomarker for DM1 with clinical and pathophysiological relevance, correlating with disease severity, presence of cardiac malfunction, and fibrosis.
New publication: TEFM variants impair mitochondrial transcription causing childhood-onset neurological disease
Lochmüller Lab Members Published as Authors in Nature Communications Study: TEFM variants impair mitochondrial transcription causing childhood-onset neurological disease.
Lochmüller Lab hosts information session on clinical research for FSHD
On Saturday June 11th the Lochmüller Lab were delighted to welcome individuals and families living with FSHD and members of the FSHD Society to the CHEO Research Institute for an information session on clinical research in FSHD.
May 2022 Issue of the Journal of Neuromuscular Diseases Available Online
Volume 9, Issue 3 of the journal of neuromuscular diseases is now available online, with almost half of the publications being open access!
CHEO Registers Tenth Patient in AMO Reach CDM Clinical Trial
As of March 14th, 2022 our site at CHEO has registered its 10th participant for AMO’s REACH-CDM trial.
Canadian Neuromuscular Disease Registry Launches New Congenital Myasthenic Syndrome Registry
We’re delighted to announce that a new registry for patients with congenital myasthenic syndrome (CMS) has just been launched within the Canadian Neuromuscular Disease Registry (CNDR). This new initiative is led by Dr. Hanns Lochmüller as an academic study as a part of Dr. Lochmüller’s CIHR foundation grant for CMS research, and supported by the NMD4C. CMS are a diverse group…
Lochmüller Lab Visits World’s Longest Skating Rink
This February the Lochmüller Lab took a break from the research benches at the CHEO RI to visit the Rideau Canal Skateway. A UNESCO world heritage site, the Rideau Canal Skateway is a 7.8 km long skating path that winds its way through downtown Ottawa and provides a beautiful way to explore the city during the winter.
January 2022 Issue of the Journal of Neuromuscular Diseases Available Online
Volume 9, Issue 1 of the journal of neuromuscular diseases is now available online, with almost half of the publications being open access!
Happy Holidays from the Lochmüller Lab
The Lochmüller Lab would like to wish everyone a happy holidays full of good cheer! The lab members have been hard at work over the last week to spread holiday cheer, and have found creative ways to get into the festive spirit..
Jarred Lau Successful in Master’s Defense
The Lochmüller Lab would like to congratulate Master’s student Jarred Lau on successfully defending his thesis this month! Jarred’s thesis looked at unsolved patients with congenital myasthenic syndromes (CMS), a rare inherited neuromuscular disease caused by disrupted signal transmission at the neuromuscular junction (NMJ).
Dr. Hanns Lochmüller Receives the Dr. George Karpati Award for Researcher of the Year
Dr. Hanns Lochmüller is the recipient of Muscular Dystrophy Canada’s Dr. George Karpati Award for Researcher of the Year! This prestigious award is presented annually to an exemplary neuromuscular clinician or researcher who has made a significant contribution to neuromuscular research, or the advancement of care of people with neuromuscular disorders.
Dr. Hanns Lochmüller, NMD4C and MDC named co-investigators on two CIHR grants awarded for research into oculopharyngeal muscular dystrophy – led by Dr C Gagnon – and into the Indirect Socio-Economic Burden of Inherited Neuromuscular Diseases – led by Dr J Warman
The Lochmüller Lab is happy to share that project applications ‘A comprehensive study of the natural history of OPMD: An essential step towards clinical trial readiness and evidence-based interventions’ and ‘BIND Study: Assessing the Indirect Socio-Economic Burden of Inherited Neuromuscular Diseases’ have been awarded Canadian Institute of Health Research (CIHR) research grants in their recent round of funding decisions!
Lochmüller Lab Welcomes New Students
Our lab is growing! We are excited to introduce two new students who have joined the Lochmüller Lab this fall. Kelly Ho Kelly has joined as a Master’s student in Cellular and Molecular Medicine to study the effects of forskolin and salbutamol in a mouse model for congenital myasthenic syndrome (CMS). She recently graduated…